EVOLUS, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
EVOLUS, INC. (EOLS) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $29.04 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2026-08-05
- 2026-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $29.04M.
- 2026-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $30.27M.
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $32.18M.
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $36.69M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value as first filed |
|---|---|---|
| 2026-06-30 | $29.04M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $30.27M 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $32.18M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $36.69M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $38.59M 10-Q · filed 2026-08-05 | |
| 2025-03-31 | $44.55M 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $44.77M 10-Q · filed 2026-08-05 | |
| 2024-09-30 | $45.03M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $44.61M 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $44.78M 10-Q · filed 2025-08-05 | |
| 2023-12-31 | $45.03M 10-K · filed 2026-03-03 | |
| 2023-09-30 | $47.40M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $47.08M 10-Q · filed 2024-11-06 | |
| 2023-03-31 | $46.65M 10-Q · filed 2024-07-31 | |
| 2022-12-31 | $46.31M 10-K · filed 2026-03-03 | |
| 2022-09-30 | $45.52M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $45.41M 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $45.02M 10-Q · filed 2023-08-02 | |
| 2021-12-31 | $44.74M 10-K · filed 2025-03-04 | |
| 2021-09-30 | $43.30M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $42.68M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $42.28M 10-Q · filed 2022-08-02 | |
| 2020-12-31 | $41.55M 10-K · filed 2023-03-08 | $41.55M 10-K · filed 2021-03-25 |
| 2020-09-30 | $33.63M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | $36.33M 10-Q · filed 2021-11-02 | |
| 2020-03-31 | $34.22M 10-Q · filed 2021-08-04 | |
| 2019-12-31 | $44.68M 10-K · filed 2022-03-03 | |
| 2019-09-30 | $48.90M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | $47.17M 10-Q · filed 2020-10-29 | |
| 2019-03-31 | $45.90M 10-Q · filed 2020-08-10 | |
| 2018-12-31 | $50.20M 10-K · filed 2021-03-25 | |
| 2018-09-30 | $51.10M 10-Q · filed 2019-11-04 | |
| 2018-06-30 | $48.80M 10-Q · filed 2019-11-04 | |
| 2018-03-31 | $40.60M 10-Q · filed 2019-08-12 | |
| 2017-12-31 | $39.70M 10-Q · filed 2019-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |